Spots Global Cancer Trial Database for papillomavirus infections
Every month we try and update this database with for papillomavirus infections cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Conservative Management in Patients Diagnosed With Grade 2 or Grade 3 CIN | NCT04115787 | High-Grade Squa... Neoplasm Regres... Disease Progres... Papillomavirus ... | 18 Years - 50 Years | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | ||
| Viral Load Determination and Biomarkers of High Risk Human Papillomavirus (HPV) - Types in HIV-positive Men | NCT00365729 | HIV Infections Papillomavirus ... Anal Intraepith... | Smear and biops... | 18 Years - | Deutsche Luft und Raumfahrt | |
| Viral Load Determination and Biomarkers of High Risk Human Papillomavirus (HPV) - Types in HIV-positive Men | NCT00365729 | HIV Infections Papillomavirus ... Anal Intraepith... | Smear and biops... | 18 Years - | Deutsche Luft und Raumfahrt | |
| Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR). | NCT06399341 | Papillomavirus ... | Papilocare vagi... | 18 Years - | Elpen Pharmaceutical Co. Inc. | |
| HPV Self-sampling for Women Who do Not Attend Cervical Cancer Screening Programme | NCT06371118 | Papillomavirus ... Early Detection... Cervix Cancer Self-Examinatio... | Directly mailed... Mailed self-sam... Standard of car... | 26 Years - 60 Years | Universidade do Porto | |
| Prevalence and Longitudinal Follow-up of Anal Lesions, HPV Infection and Associated Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo. | NCT04910438 | Papillomavirus ... HIV Infections | STIs screening ... | 18 Years - | ANRS, Emerging Infectious Diseases | |
| Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal | NCT03584308 | Papilloma Viral... Papillomavirus ... Esophageal Vira... Esophageal Verr... | Viusid® Glizigen® Viusid Placebo Glizigen Placeb... | 18 Years - 65 Years | Catalysis SL | |
| Oral Human Papillomavirus Infection in HIV-infected Men | NCT00421486 | Papillomavirus ... HIV Infections | Oral swabs for ... | 18 Years - | Deutsche Luft und Raumfahrt | |
| Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017) | NCT03546842 | Papillomavirus ... Uterine Cervica... Vulvar Neoplasm... Vaginal Neoplas... Adenocarcinoma ... Condylomata Acu... | 9vHPV vaccine | 9 Years - 26 Years | Merck Sharp & Dohme LLC | |
| A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008). | NCT01254643 | Papillomavirus ... | V503 | 9 Years - 15 Years | Merck Sharp & Dohme LLC | |
| Diversity Analysis of Vaginal Microbiota on Women With High-risk Human Papillomavirus Infection | NCT03548740 | Papillomavirus ... | Human Papilloma... | 25 Years - 50 Years | Peking Union Medical College Hospital | |
| Human Papillomavirus (HPV) Infection in Pregnancy | NCT00194311 | Papillomavirus ... Pregnancy Compl... | 13 Years - 45 Years | University of Pennsylvania | ||
| Prevalence and Longitudinal Follow-up of Anal Lesions, HPV Infection and Associated Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo. | NCT04910438 | Papillomavirus ... HIV Infections | STIs screening ... | 18 Years - | ANRS, Emerging Infectious Diseases | |
| A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007) | NCT01073293 | Papillomavirus ... | V503 Vaccine REPEVAX™ (Conco... REPEVAX™ (Non-c... | 11 Years - 15 Years | Merck Sharp & Dohme LLC | |
| HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study | NCT04694495 | Papillomavirus ... Uterine Cervica... Sexual Transmit... | 16S rRNA gene s... | 18 Years - 50 Years | Zhujiang Hospital | |
| E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer | NCT04015336 | Papillomavirus ... Oropharyngeal N... | E7 T-Cell Recep... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Oral Human Papillomavirus Infection in HIV-infected Men | NCT00421486 | Papillomavirus ... HIV Infections | Oral swabs for ... | 18 Years - | Deutsche Luft und Raumfahrt | |
| The KEN SHE Study on HPV-vaccine Efficacy | NCT03675256 | Papillomavirus ... | immediate Garda... immediate MenVe... immediate Cerva... | 15 Years - 20 Years | Massachusetts General Hospital | |
| Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities | NCT00501189 | Papillomavirus ... | human papilloma... | 18 Years - 26 Years | Eisenhower Army Medical Center | |
| Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer | NCT05388773 | Oropharynx Canc... | therapeutic con... laboratory biom... quality-of-life... intensity-modul... Cisplatin Carboplatin | 18 Years - | University of Pittsburgh | |
| Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix | NCT02346227 | Uterine Cervica... Papillomavirus ... | AV2 Placebo | 25 Years - | Universiteit Antwerpen | |
| Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis | NCT04724980 | Recurrent Respi... Papillomavirus ... Papillomavirida... | PRGN-2012 | 18 Years - | Precigen, Inc | |
| PApillomavirus in REnal Transplant Patient | NCT02845739 | Papillomavirus ... | Kidney transpla... | 18 Years - | Centre Hospitalier Universitaire de Besancon | |
| Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) | NCT04199689 | Papillomavirus ... | 9vHPV Vaccine Placebo (Saline... | 20 Years - 45 Years | Merck Sharp & Dohme LLC | |
| Self-collected Swabs for HPV Testing in 18-24 Year Old Women | NCT01101828 | Papillomavirus ... | 18 Years - 24 Years | University of Washington | ||
| A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer | NCT04044950 | Papillomavirus ... Oropharyngeal N... | E7 TCR | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) | NCT04199689 | Papillomavirus ... | 9vHPV Vaccine Placebo (Saline... | 20 Years - 45 Years | Merck Sharp & Dohme LLC | |
| Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070) | NCT01567813 | Human Papilloma... | 9 Years - 26 Years | Merck Sharp & Dohme LLC | ||
| Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis | NCT04724980 | Recurrent Respi... Papillomavirus ... Papillomavirida... | PRGN-2012 | 18 Years - | Precigen, Inc | |
| A Study of Safety, Tolerability and Immunogenicity of HPV-L2 Vaccine in Healthy Adult Male and Female Subjects | NCT03929172 | Papillomavirus ... | AAVLP-HPV Placebo | 18 Years - 45 Years | 2A Pharma AB | |
| Human Papillomavirus and Rate of Pregnancy Achieved Via Medically Assisted Procreation | NCT01894425 | Infertility Sub-fertility Papillomavirus ... | 18 Years - 60 Years | Centre Hospitalier Universitaire de Nīmes | ||
| A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts | NCT03981822 | Condylomata Acu... Papillomavirus ... Skin Diseases, ... Skin Diseases, ... Skin Diseases Sexually Transm... Sexually Transm... Warts | VP-102 and appl... Placebo | 18 Years - | Verrica Pharmaceuticals Inc. | |
| V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071) | NCT05450705 | Papillomavirus ... | 9vHPV vaccine | 9 Years - 26 Years | Merck Sharp & Dohme LLC | |
| Prevalence and Longitudinal Follow-up of Anal Lesions, HPV Infection and Associated Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo. | NCT04910438 | Papillomavirus ... HIV Infections | STIs screening ... | 18 Years - | ANRS, Emerging Infectious Diseases | |
| Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024) | NCT03903562 | Papillomavirus ... | V503 | 9 Years - 45 Years | Merck Sharp & Dohme LLC | |
| A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer | NCT04044950 | Papillomavirus ... Oropharyngeal N... | E7 TCR | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052) | NCT05285826 | Papillomavirus ... | 9vHPV Vaccine Placebo | 20 Years - 45 Years | Merck Sharp & Dohme LLC | |
| PApillomavirus in REnal Transplant Patient | NCT02845739 | Papillomavirus ... | Kidney transpla... | 18 Years - | Centre Hospitalier Universitaire de Besancon | |
| GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077) | NCT01355003 | Papillomavirus ... | 9 Years - 46 Years | Merck Sharp & Dohme LLC | ||
| High-Risk HPV Infections in Women Aged 25 to 65 | NCT00461877 | Papillomavirus ... | 25 Years - 65 Years | University of Washington | ||
| HPV Infections in Older Women | NCT00743392 | Papillomavirus ... | 25 Years - 65 Years | University of Washington | ||
| HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study | NCT04694495 | Papillomavirus ... Uterine Cervica... Sexual Transmit... | 16S rRNA gene s... | 18 Years - 50 Years | Zhujiang Hospital | |
| E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer | NCT04015336 | Papillomavirus ... Oropharyngeal N... | E7 T-Cell Recep... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients | NCT02724254 | Condyloma | AP611074 5% gel AP611074 matchi... | 18 Years - 55 Years | Vaxart | |
| Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029) | NCT00380367 | Papillomavirus ... | Quadrivalent Hu... | 9 Years - 15 Years | Merck Sharp & Dohme LLC | |
| Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands | NCT00973856 | Papillomavirus ... Warts Condylomata Acu... Epidermodysplas... | PURELL VF481 Placebo Solutio... | 18 Years - 75 Years | Cleveland Clinic Akron General | |
| Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix | NCT04072913 | Papillomavirus ... Dysplasia Cervix Cancer | Vaginal samples... | 20 Years - 65 Years | University Hospital, Bordeaux | |
| PApillomavirus in REnal Transplant Patient | NCT02845739 | Papillomavirus ... | Kidney transpla... | 18 Years - | Centre Hospitalier Universitaire de Besancon | |
| Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV) | NCT02535104 | Condylomata Acu... Papillomavirus ... Sexually Transm... | Ranpirnase Vehicle | 18 Years - 60 Years | Tamir Biotechnology, Inc. | |
| A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008). | NCT01254643 | Papillomavirus ... | V503 | 9 Years - 15 Years | Merck Sharp & Dohme LLC | |
| Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052) | NCT05285826 | Papillomavirus ... | 9vHPV Vaccine Placebo | 20 Years - 45 Years | Merck Sharp & Dohme LLC | |
| Self-collected Swabs for HPV Testing in 18-24 Year Old Women | NCT01101828 | Papillomavirus ... | 18 Years - 24 Years | University of Washington | ||
| An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED) | NCT00496626 | Papillomavirus ... | Quadrivalent Hu... Comparator: Pla... | 9 Years - 45 Years | Merck Sharp & Dohme LLC | |
| Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017) | NCT03546842 | Papillomavirus ... Uterine Cervica... Vulvar Neoplasm... Vaginal Neoplas... Adenocarcinoma ... Condylomata Acu... | 9vHPV vaccine | 9 Years - 26 Years | Merck Sharp & Dohme LLC | |
| Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma | NCT04124198 | Oropharynx Canc... Oropharynx Squa... Carcinoma, Squa... Carcinoma Oropharyngeal N... Neoplasms, Squa... Neoplasms, Glan... Neoplasms by Hi... Pharyngeal Neop... Otorhinolaryngo... Head and Neck N... Neoplasms by Si... Otorhinolaryngo... Pharyngeal Dise... Papillomavirus ... Virus Diseases DNA Virus Infec... Tumor Virus Inf... Quality of Life | Intensity-Modul... Cisplatin Nimorazole. Transoral Robot... | 18 Years - | Rigshospitalet, Denmark | |
| ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection | NCT06439433 | Cervical Intrae... Papillomavirus ... p16 Protein | Aminolaevulinic... Aminolaevulinic... Placebo | 18 Years - 45 Years | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | |
| Cantharidin and Occlusion in Verruca Epithelium | NCT03487549 | Common Wart Warts Hand Warts Papillomavirus ... DNA Virus Infec... Skin Diseases, ... Skin Diseases, ... Skin Diseases Virus Diseases Tumor Virus Inf... Verruca Vulgari... Verruca | VP-102 Canthari... VP-102 Canthari... | 2 Years - | Verrica Pharmaceuticals Inc. | |
| Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population | NCT01598779 | Condylomata Acu... | 15 Years - 45 Years | University of Buenos Aires | ||
| Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 | NCT05580341 | Cervical Cancer Genital Wart CIN VIN Papillomavirus ... | Zerun HPV-9 GARDASIL ®9 | 16 Years - 26 Years | Shanghai Zerun Biotechnology Co.,Ltd | |
| Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities | NCT00501189 | Papillomavirus ... | human papilloma... | 18 Years - 26 Years | Eisenhower Army Medical Center | |
| Diversity Analysis of Vaginal Microbiota on Women With High-risk Human Papillomavirus Infection | NCT03548740 | Papillomavirus ... | Human Papilloma... | 25 Years - 50 Years | Peking Union Medical College Hospital | |
| An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED) | NCT00496626 | Papillomavirus ... | Quadrivalent Hu... Comparator: Pla... | 9 Years - 45 Years | Merck Sharp & Dohme LLC | |
| Natural History of Human Papillomavirus (HPV) Infections in Mid-Adult Women (WHIM) | NCT01295242 | Papillomavirus ... | 30 Years - 50 Years | University of Washington | ||
| V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071) | NCT05450705 | Papillomavirus ... | 9vHPV vaccine | 9 Years - 26 Years | Merck Sharp & Dohme LLC | |
| A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts | NCT03981822 | Condylomata Acu... Papillomavirus ... Skin Diseases, ... Skin Diseases, ... Skin Diseases Sexually Transm... Sexually Transm... Warts | VP-102 and appl... Placebo | 18 Years - | Verrica Pharmaceuticals Inc. | |
| Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma | NCT04124198 | Oropharynx Canc... Oropharynx Squa... Carcinoma, Squa... Carcinoma Oropharyngeal N... Neoplasms, Squa... Neoplasms, Glan... Neoplasms by Hi... Pharyngeal Neop... Otorhinolaryngo... Head and Neck N... Neoplasms by Si... Otorhinolaryngo... Pharyngeal Dise... Papillomavirus ... Virus Diseases DNA Virus Infec... Tumor Virus Inf... Quality of Life | Intensity-Modul... Cisplatin Nimorazole. Transoral Robot... | 18 Years - | Rigshospitalet, Denmark | |
| Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population | NCT01598779 | Condylomata Acu... | 15 Years - 45 Years | University of Buenos Aires | ||
| HPV Infections in Older Women | NCT00743392 | Papillomavirus ... | 25 Years - 65 Years | University of Washington | ||
| Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women. | NCT00117884 | Papillomavirus ... | 851B 851B 851B 851B 851B 851B 851B 851B 851B 851B 851B | 18 Years - 40 Years | Takeda | |
| E7 TCR T Cells for Human Papillomavirus-Associated Cancers | NCT02858310 | Papillomavirus ... Cervical Intrae... Carcinoma In Si... Vulvar Neoplasm... Vulvar Diseases | E7 TCR cells Aldesleukin Fludarabine Cyclophosphamid... | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023) | NCT03998254 | Papillomavirus ... | V503 Gardasil | 20 Years - 45 Years | Merck Sharp & Dohme LLC | |
| Screening for HIV-Associated Anal Cancer | NCT00188292 | HIV Infections Anal Cancer Anal Dysplasia Papillomavirus ... | 18 Years - | University Health Network, Toronto | ||
| ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection | NCT06439433 | Cervical Intrae... Papillomavirus ... p16 Protein | Aminolaevulinic... Aminolaevulinic... Placebo | 18 Years - 45 Years | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | |
| Trial of Male Circumcision: HIV, Sexually Transmitted Disease (STD) and Behavioral Effects in Men, Women and the Community | NCT00124878 | HIV Infections Sexually Transm... Papillomavirus ... Genital Herpes Gonorrhea Chlamydia Infec... Syphilis Bacterial Vagin... | Male circumcisi... | 15 Years - 49 Years | Wawer, Maria J., M.D. | |
| Cantharidin and Occlusion in Verruca Epithelium | NCT03487549 | Common Wart Warts Hand Warts Papillomavirus ... DNA Virus Infec... Skin Diseases, ... Skin Diseases, ... Skin Diseases Virus Diseases Tumor Virus Inf... Verruca Vulgari... Verruca | VP-102 Canthari... VP-102 Canthari... | 2 Years - | Verrica Pharmaceuticals Inc. | |
| Screening for HIV-Associated Anal Cancer | NCT00188292 | HIV Infections Anal Cancer Anal Dysplasia Papillomavirus ... | 18 Years - | University Health Network, Toronto | ||
| Clinical Effectiveness of PAPILOCARE® in Regression of Cervix HPV Cytological Abnormalities (PAPILOBS GR). | NCT06399341 | Papillomavirus ... | Papilocare vagi... | 18 Years - | Elpen Pharmaceutical Co. Inc. | |
| A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts | NCT03981822 | Condylomata Acu... Papillomavirus ... Skin Diseases, ... Skin Diseases, ... Skin Diseases Sexually Transm... Sexually Transm... Warts | VP-102 and appl... Placebo | 18 Years - | Verrica Pharmaceuticals Inc. | |
| Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV) | NCT02535104 | Condylomata Acu... Papillomavirus ... Sexually Transm... | Ranpirnase Vehicle | 18 Years - 60 Years | Tamir Biotechnology, Inc. | |
| Human Papillomavirus and Rate of Pregnancy Achieved Via Medically Assisted Procreation | NCT01894425 | Infertility Sub-fertility Papillomavirus ... | 18 Years - 60 Years | Centre Hospitalier Universitaire de Nīmes |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
